Progression of coronary artery calcification in conventional hemodialysis, nocturnal hemodialysis, and kidney transplantation
Open Access
- 30 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0244639
Abstract
Introduction: Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) and is strongly associated with vascular calcification. An important driver of vascular calcification is high phosphate levels, but these become lower when patients initiate nocturnal hemodialysis or receive a kidney transplant. However, it is unknown whether nocturnal hemodialysis or kidney transplantation mitigate vascular calcification. Therefore, we compared progression of coronary artery calcification (CAC) between patients treated with conventional hemodialysis, nocturnal hemodialysis, and kidney transplant recipients.Methods: We measured CAC annually up to 3 years in 114 patients with ESRD that were transplantation candidates: 32 that continued conventional hemodialysis, 34 that initiated nocturnal hemodialysis (≥4x 8 hours/week), and 48 that received a kidney transplant. We compared CAC progression between groups as the difference in square root transformed volume scores per year (ΔCAC SQRV) using linear mixed models. Reference category was conventional hemodialysis.Results: The mean age of the study population was 53 ±13 years, 75 (66%) were male, and median dialysis duration was 28 (IQR 12–56) months. Median CAC score at enrollment was 171 (IQR 10–647), which did not differ significantly between treatment groups (P = 0.83). Compared to conventional hemodialysis, CAC progression was non-significantly different in nocturnal hemodialysis -0.10 (95% CI -0.77 to 0.57) and kidney transplantation -0.33 (95% CI -0.96 to 0.29) in adjusted models.Conclusions: Nocturnal hemodialysis and kidney transplantation are not associated with significantly less CAC progression compared to conventional hemodialysis during up to 3 years follow-up. Further studies are needed to confirm these findings, to determine which type of calcification is measured with CAC in end-stage renal disease, and whether that reflects cardiovascular risk.Keywords
Funding Information
- Amgen Nederland
- Baxter Nederland
- Novartis Pharma
- Fresenius Medical Care
- Wellerdieck-de Goedefonds
- Roche
- Shire
This publication has 34 references indexed in Scilit:
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone DisorderJournal of the American Society of Nephrology, 2012
- Progression of coronary artery calcification in renal transplant recipientsNephrology Dialysis Transplantation, 2011
- Coronary Calcification in Patients with Chronic Kidney Disease and Coronary Artery DiseaseClinical Journal of the American Society of Nephrology, 2009
- Progression of Coronary Artery Calcification in Renal Transplantation and the Role of Secondary Hyperparathyroidism and InflammationClinical Journal of the American Society of Nephrology, 2009
- Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2007
- Reduced Plasma Pyrophosphate Levels in Hemodialysis PatientsJournal of the American Society of Nephrology, 2005
- Natural history of vascular calcification in dialysis and transplant patientsNephrology Dialysis Transplantation, 2004
- Cardiac calcification in adult hemodialysis patientsJACC, 2002
- INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUESThe Lancet, 1989